{"disease":{"id":"refractory-myasthenia-gravis","name":"refractory myasthenia gravis"},"drugs":{"marketed":[{"drug_id":"eculizumab","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"soliris","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02301624","title":"Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05332587","title":"Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07337785","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Daishi Tian","has_results":false},{"nct_id":"NCT07243366","title":"Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Guangdong ProCapZoom Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT06965309","title":"Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)","phase":"NA","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Shenzhen MagicRNA Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT06419166","title":"An Exploratory Clinical Study of GC012F Injection for Refractory gMG","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}